Shanxi Zhendong Pharmaceutical (300158) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanxi Zhendong Pharmaceutical (300158) has a cash flow conversion efficiency ratio of -0.055x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-197.94 Million ≈ $-28.96 Million USD) by net assets (CN¥3.63 Billion ≈ $530.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Shanxi Zhendong Pharmaceutical (300158) balance sheet quality index to measure how much of total assets are equity-financed.
Shanxi Zhendong Pharmaceutical - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Shanxi Zhendong Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Shanxi Zhendong Pharmaceutical to evaluate the quality of earnings relative to operating cash generation.
Shanxi Zhendong Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanxi Zhendong Pharmaceutical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Red Violet Inc
NASDAQ:RDVT
|
0.100x |
|
Karnov Group AB
ST:KAR
|
0.108x |
|
Slate Grocery REIT
TO:SGR-UN
|
0.019x |
|
Finnair Oyj
HE:FIA1S
|
0.160x |
|
Shenzhen Topway Video Communication Co Ltd
SHE:002238
|
0.018x |
|
Zhejiang Dehong Automotive
SHG:603701
|
-0.014x |
|
Luyin Investment Group Co Ltd
SHG:600784
|
-0.007x |
|
Shenzhen Comix Group Co Ltd
SHE:002301
|
0.017x |
Annual Cash Flow Conversion Efficiency for Shanxi Zhendong Pharmaceutical (2007–2024)
The table below shows the annual cash flow conversion efficiency of Shanxi Zhendong Pharmaceutical from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see 300158 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.66 Billion ≈ $535.61 Million |
CN¥-149.82 Million ≈ $-21.92 Million |
-0.041x | -10.85% |
| 2023-12-31 | CN¥5.14 Billion ≈ $752.74 Million |
CN¥-189.95 Million ≈ $-27.80 Million |
-0.037x | -323.47% |
| 2022-12-31 | CN¥5.22 Billion ≈ $764.33 Million |
CN¥86.31 Million ≈ $12.63 Million |
0.017x | -53.21% |
| 2021-12-31 | CN¥8.05 Billion ≈ $1.18 Billion |
CN¥284.45 Million ≈ $41.62 Million |
0.035x | -10.36% |
| 2020-12-31 | CN¥5.63 Billion ≈ $824.31 Million |
CN¥221.94 Million ≈ $32.48 Million |
0.039x | +15.04% |
| 2019-12-31 | CN¥5.44 Billion ≈ $796.21 Million |
CN¥186.35 Million ≈ $27.27 Million |
0.034x | +18.89% |
| 2018-12-31 | CN¥5.36 Billion ≈ $784.69 Million |
CN¥154.48 Million ≈ $22.60 Million |
0.029x | +255.11% |
| 2017-12-31 | CN¥5.56 Billion ≈ $813.28 Million |
CN¥45.09 Million ≈ $6.60 Million |
0.008x | +195.63% |
| 2016-12-31 | CN¥5.27 Billion ≈ $771.41 Million |
CN¥-44.72 Million ≈ $-6.54 Million |
-0.008x | -111.34% |
| 2015-12-31 | CN¥2.03 Billion ≈ $297.12 Million |
CN¥151.84 Million ≈ $22.22 Million |
0.075x | +101.19% |
| 2014-12-31 | CN¥1.97 Billion ≈ $288.29 Million |
CN¥73.23 Million ≈ $10.72 Million |
0.037x | +197.00% |
| 2013-12-31 | CN¥1.96 Billion ≈ $286.56 Million |
CN¥-75.04 Million ≈ $-10.98 Million |
-0.038x | -138.43% |
| 2012-12-31 | CN¥1.90 Billion ≈ $277.96 Million |
CN¥189.40 Million ≈ $27.72 Million |
0.100x | +308.83% |
| 2011-12-31 | CN¥1.86 Billion ≈ $271.95 Million |
CN¥-88.73 Million ≈ $-12.98 Million |
-0.048x | -362.53% |
| 2010-12-31 | CN¥1.78 Billion ≈ $260.67 Million |
CN¥32.40 Million ≈ $4.74 Million |
0.018x | -84.54% |
| 2009-12-31 | CN¥359.31 Million ≈ $52.58 Million |
CN¥42.28 Million ≈ $6.19 Million |
0.118x | -5.43% |
| 2008-12-31 | CN¥266.72 Million ≈ $39.03 Million |
CN¥33.18 Million ≈ $4.86 Million |
0.124x | -82.94% |
| 2007-12-31 | CN¥176.42 Million ≈ $25.82 Million |
CN¥128.65 Million ≈ $18.82 Million |
0.729x | -- |
About Shanxi Zhendong Pharmaceutical
Shanxi Zhendong Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sales of pharmaceutical drugs in China. It offers drugs for various fields, including tumors, dermatology, digestion, urology, and cardio-cerebral drugs. The company also provides Chinese herbal medicines. Shanxi Zhendong Pharmaceutical Co.,Ltd was founded in 1995 and is b… Read more